Emtriva: profile and news

Hamilton Students Win Outstanding Poster Presentation Awards at ...  07 Mar 2006
Karilyn presented "Analysis of Raloxifene and its Derivative's Binding Affinities to the alpha Estrogen Receptor Ligand Binding Domain" while Meghan presented ... - Hamilton College News,

Low Endogenous Estradiol, Raloxifene (Evista), Linked to Decreased ...  Feb 21, 2006
...women who have low estradiol levels are at decreased risk of stroke, as are women with higher endogenous estradiol who take raloxifene (Evista), according to a ... - DG News

Menopause drug may have positive effect on heart  Feb 24, 2006
...of the drug manufacturer Eli Lilly, a study found that women who have increased risk for cardiovascular events and who took the drug raloxifene (Evista) for ... - INQ7.net,

Natural Estrogen Affects Stroke Risk, Study Suggests  Feb 20, 2006
It involved 7,290 women who participated in a recent study of raloxifene, a "designer estrogen" that blocks that hormone's action in some parts of the body ... - International News Service,

Women With Higher Natural Estrogen Levels Have Increased Risk of ...  Feb 22, 2006
Jennifer Lee of the University of California-San Francisco and colleagues looked at 7,290 women who were participating in a study on raloxifene -- a drug that ... - Kaiser network.org,

What Causes Osteoporosis?  Feb 6, 2006
...previously are often paired with bisphosphonates like Alendronate and Risedronate, selective estrogen receptor modulators (SERMs) like Raloxifene, and hormonal ... - DailyIndia.com,

Woman‘s Natural Estrogen Tied to Stroke  Feb 17, 2006
The study‘s main aim was testing raloxifene for treating the bone-thinning disease osteoporosis, a use for which the drug ultimately won approval. ... - Brocktown News,

FDA Censorship Wins $36 Million in Fines and Penalties  Feb 8, 2006
American Medical Association (JAMA), a prominent peer-reviewed scientific journal that presented scientific data supporting the use of raloxifene (the chemical ... - American Council on Science and Health,

ASA: Serum Estradiol Levels Linked to Postmenopausal Stroke  Feb 20, 2006
They added that women that women who had high levels of estradiol and who were taking Evista (raloxifene) had a slight trend toward reduced stroke risk. ... - MedPage Today,

HOPE for bone health  Feb 19, 2006
..."Newer drugs called selective estrogen receptor modulators, such as Evista or Raloxifene, seem to have a favorable effect on the bones, and they do not ... - Pittsburgh Tribune-Review,

Dietary Modification and Risk of Breast Cancer  Feb 8, 2006
8 In women at risk of developing breast cancer, pharmacological interventions with antiestrogens (tamoxifen and raloxifene) can reduce this risk. ... - Journal of American Medical Association (subscription),

Procter to develop Nastech osteoporosis drug  Feb 15, 2006
...per cent market share with its bisphosphonate alendronate (Fosamax), Lilly 17 per cent of the market, thanks primarily to its SERM raloxifene (Evista), while ... - In-PharmaTechnologist.com,

Menopausal changes  Feb 14, 2006
Certain medicines like tamoxifen used for chemotherapy and raloxifene for prevention and treatment of osteoporosis can trigger hot flushes. ... - Malaysia Star,

SCOLR Pharma Reports Positive Ondansetron Clinical Results, New ...  Feb 16, 2006
Turner further noted, "On the basis of these positive results, we plan to optimize our raloxifene and ondansetron formulations for continued evaluation and to ... - Genetic Engineering News,

It is Predicted in the Next Ten Years the Demand for Drugs to ...  Feb 3, 2006
Lilly's 17% market share comes primarily from sales of the selective estrogen receptor modulator (SERM) raloxifene (Evista), and Procter & Gamble holds a 13 ... - International News Service,

Scolr's ondansetron tablets found to outperform Glaxo rival  Feb 17, 2006
..."On the basis of these positive results, we plan to optimize our raloxifene and ondansetron formulations for continued evaluation and to expand the application ... - Pharmaceutical Business Review

FDA Censorship Wins $36 Million in Fines and Penalties  Feb 8, 2006
American Medical Association (JAMA), a prominent peer-reviewed scientific journal that presented scientific data supporting the use of raloxifene (the chemical ... - American Council on Science and Health,

What Causes Osteoporosis?  Feb 6, 2006
...previously are often paired with bisphosphonates like Alendronate and Risedronate, selective estrogen receptor modulators (SERMs) like Raloxifene, and hormonal ... - DailyIndia.com,

It is Predicted in the Next Ten Years the Demand for Drugs to ...  Feb 3, 2006
Lilly's 17% market share comes primarily from sales of the selective estrogen receptor modulator (SERM) raloxifene (Evista), and Procter & Gamble holds a 13 ... - International News Service,

Lilly Reports Q4 EPS of $.64, or $.80 Excluding Charges; 2005 EPS ...  Jan 26, 2006
Amylin Pharmaceuticals) Cialis(R) (tadalafil, ICOS), Lilly ICOS LLC Cymbalta(R) (duloxetine hydrochloride, Lilly) Evista(R) (raloxifene hydrochloride, Lilly ... - PR Newswire (press release),

No Link Between Hormone Levels and Tamoxifen Response in High-Risk ...  Jan 24, 2006
Previously, a study of raloxifene (another drug that has been studied for breast cancer prevention) reported that raloxifene showed the greatest effect in ... - Cancer Consultants (press release),

Lilly Reports Q4 EPS of $.64, or $.80 Excluding Charges; 2005 EPS ...  Jan 26, 2006
Amylin Pharmaceuticals) Cialis® (tadalafil, ICOS), Lilly ICOS LLC Cymbalta® (duloxetine hydrochloride, Lilly) Evista® (raloxifene hydrochloride, Lilly ... - Yahoo! News (press release)

Your bones' best friend is an active lifestyle  Jan 12, 2006
SERMs (selective estrogen receptor modulators) such as raloxifene act like the female sex hormone estrogen to increase bone density and prevent fractures of ... - Toronto Star,

Bruker help Chinese fight counterfeit drugs  Jan 20, 2006
...of Pfizer's Lipitor (atorvastatin) and Viagra (sildenafil), and an unapproved product promoted as a generic version of Eli Lilly's Evista (raloxifene) to US ... - In-PharmaTechnologist.com,

Other highlights in the January 18 JNCI  Jan 17, 2006
Although tamoxifen is commonly used to treat breast cancer in postmenopausal women, one study suggested that raloxifene, a selective estrogen receptor ... - EurekAlert (press release),

Fighting Cancer May Mean Fighting 'Fate'  Dec 8, 2005
...vs. raloxifene in preventing breast malignancy), 11 percent said they believed getting cancer was simply a matter of fate. Fatalism ... - Forbes

Fighting cancer may mean fighting 'fate'  Dec 8, 2005
Even among women who agreed to join the trial (which will compare the effectiveness of tamoxifen versus raloxifene in preventing breast malignancy), 11 percent ... - WTOP,

Major Ovarian Cancer Clinical Study Announced At Yale Using ...  Nov 28, 2005
USC Study Shows Raloxifene May Increase Ovarian Cancer Growth Rate (July 5, 2001) -- The drug raloxifene may increase the growth rate of ovarian cancer and its ... - Science Daily (press release)

Family genetic mutations may increase cancer risk  Nov 28, 2005
..."I've tried to do everything I can do reduce my risk.". Toyama was a part of Marshfield Clinic's five-year study of two drugs, Tamoxifen and Raloxifene. ... - Stevens Point Journal,

SCOLR Pharma Reports Third Quarter and Nine-Month Results  Nov 14, 2005
...-- Successful completion of pilot bioavailability testing in Canada of Controlled Delivery Technology (CDT(R)) raloxifene tablets. ... - Genetic Engineering News,

Tamoxifen cuts breast cancer, but many still wary  Nov 16, 2005
The Pittsburgh-based oncology network, known as the NSABP, is testing Eli Lilly's osteoporosis drug raloxifene, brand name Evista, against tamoxifen. ... - Philadelphia Inquirer,

Smoothing the transition  Nov 22, 2005
...development of osteoporosis. In Australia we have only one drug in this class, raloxifene, which increases bone density. However, the ... - AustralianDoctor.com (subscription),

Study shows tamoxifen can prevent cancer for years  Nov 15, 2005
The group is also studying tamoxifen's ability to prevent the disease in comparison to raloxifene, an osteoporosis drug sold under the brand Evista by Eli ... - Malaysia Star,

Long-Term Study Proves Tamoxifen Helps Prevent Breast Cancer  Nov 15, 2005
Fishman said. Raloxifene, a drug originally developed to treat osteoporosis, is just one of these candidate drugs, he noted. And ... - Forbes

Final Results from the NSABP Breast Cancer Prevention Trial ...  Nov 15, 2005
...“We hope that other breast cancer prevention clinical trials, such as STAR, the Study of Tamoxifen and Raloxifene, help us identify drugs that maximize the ... - National Institutes of Health (press release)

Few takers for preventive drug  Nov 15, 2005
It thus set the stage for ongoing clinical studies of other drugs, including raloxifene, anastrozole and exemestane, which may have fewer side effects than ... - Pittsburgh Post Gazette,

Study Finds Tamoxifen Reduces Long-Term Risk of Breast Cancer  Nov 16, 2005
The same research group is comparing tamoxifen to the Eli Lilly osteoporosis drug raloxifene, also known as Evista with test results expected in the spring. ... - Newsinferno.com,

Tamoxifen reduces long-term risk of cancer  Nov 16, 2005
The group is also studying Tamoxifen's ability to prevent the disease in comparison to raloxifene, an osteoporosis drug. Those results are due next spring. ... - News-Medical.net,

Practical Geriatrics: Depression, Cognition, and Anxiety Among ...  Nov 8, 2005
...or a premature menopause state can be induced among patients with breast cancer by antiestrogen treatments, which include tamoxifen, raloxifene, and letrozole. ... - Psychiatric Services (subscription)

Benefits Of Longer-term Tamoxifen Use May Take Years To Appear  Oct 24, 2005
Raloxifene After Tamoxifen Not Beneficial, According To New Study (February 20, 2002) -- Taking raloxifene after five years of tamoxifen therapy does not ... - Science Daily (press release)

Combating cancer  Oct 29, 2005
Scientists also are studying a number of drugs that could reduce cancer risk: aspirin for colon cancer, tamoxifen and raloxifene for breast cancer, finasteride ... - Cincinnati Enquirer,

Funds to keep cancer-free: Federal grant will allow local studies ...  Oct 27, 2005
Drew, a 57-year-old Decatur woman, has participated in a national prevention trial, the study of Tamoxifen and Raloxifene, for three years. ... - Herald & Review,

Women under 70 denied brittle bone drug  Oct 21, 2005
National Institute for Clinical Excellence, cover a type of osteoporosis drug known as bisphosphonates, plus other medicines called raloxifene and strontium ... - Daily Mail - UK,

Lilly Reports $.73 EPS and 10 Percent Sales Growth in the Third ...  Oct 20, 2005
R) (pemetrexed, Lilly) Cialis(R) (tadalafil, ICOS), Lilly ICOS LLC Cymbalta(R) (duloxetine hydrochloride, Lilly) Evista(R) (raloxifene hydrochloride, Lilly ... - PR Newswire (press release),

Cancer Society 'making strides' against illness  Oct 17, 2005
Research supported by the American Cancer Society led to the development of tamoxifen and raloxifene, drugs that can reduce breast cancer recurrence, as well ... - Daily News Journal (subscription),

Menopause In Women - Part II  Oct 18, 2005
...the esophagus. Selective Estrogen Receptor Modulators, or SERMs, such as Evista (Raloxifene), also reduce fracture risk. But SERMs ... - The Bahama Journal,

Cancer survivors celebrate life, inspire others  Oct 22, 2005
Options include a lumpectomy or mastectomy followed by radiation therapy and/or chemotherapy and/or hormonal therapy such as Tamoxifen, Raloxifene or Arimadex. ... - Lexington Clipper Herald,

Management Strategies of Dyslipidemia in the Elderly  Oct 11, 2005
...from and is on the trial steering committee for Eli Lilly, AstraZeneca, and Pfizer, and is a consultant for the Eli Lilly Raloxifene Advisory Committee; Heart ... - Medscape (subscription)

Management Strategies of Dyslipidemia in the Elderly  11 Oct 2005
...from and is on the trial steering committee for Eli Lilly, AstraZeneca, and Pfizer, and is a consultant for the Eli Lilly Raloxifene Advisory Committee; Heart ... - Medscape (subscription)

Proven steps to a longer life  Sep 26, 2005
Scientists also are studying a number of drugs that could reduce cancer risk: aspirin for colon cancer, tamoxifen and raloxifene for breast cancer, finasteride ... - Chillicothe Gazette,

SCOLR Pharma, Inc. Issued Second Patent for Platform Used to ...  Sep 12, 2005
SCOLR Pharma recently announced the successful completion of a pilot bioavailability study of CDT-based raloxifene formulations in the first human application ... - Genetic Engineering News,

Women Do Not Get Enough Vitamin D to Protect Their Bones, Health ...  Sep 20, 2005
Bisphosphonates (alendronate, etidronate, risedronate), selective oestrogen receptor modulators (raloxifene) and parathyroid hormone (teriparatide) for the ... - PR Newswire UK (press release),

DATAMONITOR: FDA Rejects Pfizer's Oporia  Sep 16, 2005
...trials has been published, although data from Phase II studies suggested that the drug was at least as effective as Eli Lilly’s Evista (raloxifene) and may ... - PharmaLive.com (press release),

The potential for drug interactions with EMTRIVA has been studied in combination with indinavir, stavudine, famciclovir, and tenofovir disoproxil fumarate. There were no clinically significant drug interactions for any of these drugs.

 


Chemical IUPAC Name
4-amino-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]-pyrimidin-2-one

Chemical Formula
C8H10FN3O3S

Half Life
10 hours

Drug Type
Approved Drug

# Accession No
APRD00226

CAS Registry Number
143491-57-0